The Mediterranean diet and menopausal health: An EMAS position statement

Antonio Cano a,b,⁎, Skye Marshall b,c, Irene Zolfaroli a, Johannes Bitzer d, Iuliana Ceausu e, Peter Chedraui f, Fatih Durmusoglu g, Risto Erkkola h, Dimitrios G. Goulis i, Angelica Lindén Hirschberg j, Ludwig Kiesel k, Patrice Lopes l, Amos Pines m, Mick van Trotsenburg n, Irene Lambrinoudaki o, Margaret Rees p

a Department of Pediatrics, Obstetrics and Gynecology, University of Valencia and INCLIVA, Valencia, Spain
b Nutrition Research Australia, New South Wales, Australia
c Bond University Nutrition & Dietetics Research Group, Faculty of Health Sciences and Medicine, Bond University, Queensland, Australia
d Department of Obstetrics and Gynecology, University Hospital, Basel, Switzerland
e Department of Obstetrics and Gynecology I, “Dr. I. Cantacuzino” Hospital, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
f Instituto de Investigación e Innovación de Salud Integral (ISAIN), Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador
g Istanbul Medipol International School of Medicine, Istanbul, Turkey
h Department of Obstetrics and Gynecology, University Central Hospital Turku, Finland
i Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Greece
j Department of Women’s and Children’s Health, Karolinska Institute and Department of Obstetrics and Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden
k Department of Gynecology and Obstetrics, University of Münster, Münster, Germany
l Nantes, France Polytechmine de l’Atlantique Saint Herblain, F 44819 St Herblain France, Université de Nantes F 44093 Nantes Cedex, France
m Sackler Faculty of Medicine, Tel-Aviv University, Israel
n Department of Obstetrics and Gynecology, University Hospital St. Poelten-Lilienfeld, Austria
o Second Department of Obstetrics and Gynecology, Arretonio Hospital, Medical School, National and Kapodistrian University of Athens, Greece
p Women’s Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK

ARTICLE INFO

Keywords:
Mediterranean diet
Health
Non-communicable disease
Menopause
Women’s health

ABSTRACT

Introduction: Globally, 985 million women are aged 50 and over, leading to increasing concerns about chronic conditions such as cardiovascular disease, osteoporosis, dementia, and cognitive decline, which can adversely affect quality of life and independent living.

Aim: To evaluate the evidence from observational studies and randomized trials on the effects of the Mediterranean diet on short- and long-term menopausal health: estrogen deficiency symptoms, cardiovascular disease, osteoporosis, cognitive and mental health, breast cancer, and all-cause mortality.

Materials and methods: Literature review and consensus of expert opinion.

Summary recommendations: The Mediterranean diet is a non-restrictive dietary pattern common in the olive-growing areas of the Mediterranean basin. It may improve vasomotor symptoms, cardiovascular risk factors such as blood pressure, cholesterol and blood glucose levels, as well as mood and symptoms of depression. Long-term adherence may: improve cardiovascular risk and events, and death; improve bone mineral density; prevent cognitive decline; and reduce the risk of breast cancer and all-cause mortality.

1. Introduction

Women are living longer. The United Nations has estimated that, worldwide, 985 million women in 2020 are aged 50 and over. The figure is expected to rise to 1.65 billion by 2050 [1]. Not surprisingly, the immediate and long-term sequelae of postmenopausal estrogen deficiency and aging present an enormous problem to healthcare systems. There are increasing concerns about non-communicable diseases (NCDs) such as cardiovascular disease (CVD), osteoporosis, dementia, and cognitive decline, which can adversely affect quality of life and independent living.

The optimization of diet is increasingly being accepted as playing a
role in the strategies to reduce the risk of NCDs and to promote women's health at the menopause. The concept has been recognized worldwide [2]. The EAT-Lancet Commission [3,4] has promoted the concept that a nutritionally optimal dietary pattern is compatible with the United Nations Sustainable Developmental Goals [5]. In addition to meeting age- and gender-related nutrient requirements, there has been increasing focus on the other health benefits of specific dietary patterns, such as the Mediterranean diet (MedDiet) [6].

Growing international interest in the MedDiet has led to many large observational studies with follow-up extending over decades as well as randomized controlled trials (RCTs). These have found a causal link between the MedDiet and health outcomes [7–9]. Overall, both all-cause and cause-specific mortality are reduced by the MedDiet [10–12]. Further, the MedDiet has been shown to be feasible in non-Mediterranean populations, with some health services implementing it within “usual care” for NCDs [6,13–17].

This position statement considers evidence from observational studies and RCTs which examine the MedDiet and focuses on its role in women's post-reproductive health. It considers the effects of the MedDiet on short-term and long-term menopausal health: estrogen deficiency symptoms, CVD, osteoporosis, cognitive and mental health, breast cancer and all-cause mortality.

2. Composition of the Mediterranean diet

The MedDiet is the dietary pattern prevailing in the olive-growing areas of the Mediterranean basin; it has been influenced by various civilizations over the centuries [18]. In classical Greece and then in the Roman Empire it was based on bread, olive oil, and wine [19]. The Arabs and the Turkish Empire introduced spices from the Orient, and the role of legumes, grains and nuts was reinforced. New components of the region’s diet came with the discovery of the Americas, which introduced a variety of foods, including tomatoes, chilies, and new varieties of legumes. The dietary pattern is plant-dominant, characterized by daily consumption of fruit, vegetables, breads, other forms of cereals, beans and seeds, olive oil and nuts. Dairy products (principally cheese and yogurt), eggs and fish are also eaten. Fish consumption varies with distance to the sea. The MedDiet includes low to moderate wine intake with meals, and some meat, usually poultry (chicken), rabbit, lamb, or goat. The MedDiet is low in saturated fat as olive oil and nuts are the major source of fat [19]. In addition, an important feature of the diet is frugality, imposed by the scarcity of food during winter or during periods of austerity. Also, many of those who adopt the MedDiet are physically active. As the MedDiet is not based on dietary restriction and reflects the usual dietary pattern of diverse cultures, adherence is often higher than to other diets, such as the Dietary Approaches to Stop Hypertension (DASH) diet [6].

3. The Mediterranean diet and menopausal symptoms

A single cohort study has examined the effect of the MedDiet on vasomotor symptoms (VMS), such as hot flushes and night sweats, and there is a paucity of data on other estrogen-deficiency symptoms, such as those due to vulvo-vaginal atrophy. A cohort of over 6000 women who had passed through a natural menopause in Australia found that adherence to a MedDiet decreased the risk of experiencing VMS by 20 % (OR: 0.80 [95 %CI: 0.69 – 0.92] P < 0.001) [20].

The Women’s Health Initiative (n = 6104 post-menopausal women with VMS) RCT delivered intensive education and counselling to achieve a dietary pattern with high plant intake similar to the MedDiet. In women with mild VMS, the plant-based diet increased the likelihood of elimination of VMS within 12 months by 14 % (OR: 1.14 [95 %CI: 1.01–1.28] P = 0.04); however, there was no improvement for women with moderate to severe VMS [21,22]. The Study of Women’s Health Across the Nation (SWAN) obtained negative results when looking at the effect of nutrients in general on VMS in pre- and peri-menopausal women [23], suggesting it is the broader dietary pattern rather than meeting nutrient requirements which affects VMS.

4. The Mediterranean diet and cardiovascular disease

Cardiovascular disease has traditionally been seen as more of a men’s problem [24]. However, CVD, including both coronary heart disease (CHD) and stroke, is the main cause of death in women worldwide. The World Health Organization estimated that, in 2015, CVD was responsible for 31 % of all global deaths (17.7 million deaths) [25]. In Europe, CVD is responsible for 2.1 million deaths (49 % of all deaths) in women annually [26]. Not surprisingly, the main research focus regarding the benefits of the MedDiet has been on CVD. The first study was the observational Seven Countries Study, initiated after low rates of CHD in Naples were noted in the early 1950s [8]. It investigated the association of the MedDiet with CHD and stroke [9] and was followed by numerous observational studies and RCTs internationally. The latter studies tended to be more sophisticated in adjusting for variables such as body weight which affect CVD risk.

4.1. Observational studies

The largest and longest observational studies which examine the MedDiet and CVD are shown in Table 1. All the studies found that adherence to the MedDiet reduced the incidence and mortality of CVD. Studies which examined outcomes according to sex reported stronger findings in women [27,28]. Furthermore, systematic reviews and meta-analyses have found mean relative risks of CVD around 0.70 and 0.80 in comparisons of women following the MedDiet and those not [29–34].

Synthesizing these findings, a recent meta-analysis of observational studies found that high adherence to the MedDiet by women reduced their relative risk of CHD and acute myocardial infarction (MI) by 30 % and of stroke by 17 % [24].

4.2. Randomized controlled trials

The study that has received the most interest has been the PREvención con Dieta MEDiterránea (PREDIMED) study [45]. A primary prevention RCT, PREDIMED examined whether the unrestricted-calorie MedDiet was superior to a low-fat diet for CVD protection in older men and postmenopausal women with CVD risk factors. The 7447 participants (57 % women) were randomized to one of three arms, two of them consisting of the MedDiet, one supplemented with extra-virgin olive oil and the other with nuts, and the third consisting of a low-fat diet. Energy restriction was not advised, nor was physical activity promoted. The primary objective was to measure the rate of clinical CVD events such as MI and stroke, and CVD death. The study was prematurely stopped after 4.8 years of follow-up due to the clear benefits observed in both the olive oil (HR: 0.69 [95 %CI: 0.53 – 0.91]) and nut arms (HR: 0.72 [95 %CI: 0.54 – 0.95]). Consequently, PREDIMED has become a landmark study because, for the first time, it observed a clear causal association between MedDiet and objective CVD outcomes. However, gender differences were not reported.

The Lyon Heart Study was a secondary prevention RCT in men and women aged under 70 years who had experienced a first MI. It investigated whether a MedDiet enriched with alpha-linoleic acid reduced the rates of cardiac death and non-fatal acute MI [46]. After a mean follow-up of 27 months, the risk ratio for the two main endpoints combined was 0.27 (95 %CI: 0.12 – 0.59) and overall mortality 0.30 (95 %CI: 0.11 – 0.82) in the MedDiet group. Differences between women and men were not presented.

The Mediet Project randomized trial, with a sample of post-menopausal women, examined the effects of providing MedDiet cooking lessons with the instruction to use these skills at home. After 1 year, participants in the intervention group had improved their cholesterol levels and quality of life compared with the controls [47].
A 2019 Cochrane systematic review that analyzed data from 30 RCTs, in both sexes and all age groups, including the above-mentioned RCTs, concluded that the trial evidence on the effectiveness of the MedDiet in the risk reduction or management of CVD was still uncertain due to statistical heterogeneity [48,49]. On the other hand, recommending an eating style can help women make positive changes. The MedDiet is included in nutrition guidelines to promote health and decrease CVD burden [16,17,50].

5. The Mediterranean diet and cardiovascular risk factors

5.1. Blood pressure

The effect of the MedDiet on blood pressure has been investigated in both healthy and hypertensive individuals. There is a consensus that the MedDiet does decrease blood pressure but that the size of the effect is small. Observational studies have shown reductions of 2 – 3 mmHg and 1 – 2 mmHg in mean systolic and diastolic blood pressure, respectively [51]. The Hellenic National Nutrition and Health Survey (2013–2015,
Evidence from RCTs shows that the MedDiet is associated with beneficial, although small, lipid changes. A reduction of up to 0.2 mmol/L (7.7 mg/dL) has been found for total cholesterol and low-density lipoprotein cholesterol but little or no effect on high-density lipoprotein cholesterol has been found [48].

The PREDIMED study has generated a number of sub-studies in which changes in lipoproteins have been investigated [56-58]. Most of them support shifts in lipoprotein subfractions to a less atherogenic pattern, but more evidence is required regarding the effect specifically for menopausal and postmenopausal women. The Mediet Project RCT (see above), which recruited postmenopausal women, found a trend towards improved cholesterol levels in the MedDiet intervention group, compared with controls; however, specific levels were not reported [47].

5.3. Central obesity and fat distribution

Central obesity is associated with chronic low-grade inflammation, and is a risk factor for cardiometabolic syndrome. It has been investigated as one of the outcomes of the MedDiet. The conclusions from some studies are unclear as some MedDiets were low in calorie as well. Thus it is hard to assess whether any effects seen were the result of the foods included in the diet or the calorie restriction [see for example [59]]. Analysis of intervention trials overall shows that the MedDiet prevents an increase in central obesity [60]. Changes in waist circumference range between 0.5 cm and 7 cm. In RCTs which recruited only women, waist circumference decreased by 5.2-6.5 cm. Improvements in waist-hip ratio were also noted. A limited effect on waist circumference was observed in the unrestricted-calorie high-vegetable-fat MedDiet PREDIMED study [61]. Thus, the adjusted difference in 5-year changes in waist circumference was -0.466 cm (-1.109 to 0.176; p = 0.154) in the MedDiet with olive oil group and -0.923 cm (-1.604 to -0.241; p = 0.008) in the MedDiet with nut group, compared with the control group.

Two randomized studies have provided information about fat distribution. One, using magnetic resonance imaging, found that a Mediterranean/low-carbohydrate diet mobilized specific ectopic fat depots, decreasing intraabdominal, intrapericardial, and pancreatic fat deposition [62]. Another study with dual-energy X-ray absorptiometry (DXA) found a reduction in subcutaneous fat and waist circumference but not visceral adipose tissue or other body composition measures [63].

5.4. Metabolic syndrome and type 2 diabetes mellitus

A cluster of risk factors for CVD and type 2 diabetes mellitus, which occur together more often than by chance alone, are known as the metabolic syndrome. The risk factors include raised blood pressure, dyslipidemia (raised triglycerides and low-density lipoprotein [LDL] cholesterol and lowered high-density lipoprotein [HDL] cholesterol), raised fasting glucose, and central obesity [64]. The effect of the MedDiet on metabolic syndrome has been widely examined in observational and intervention studies.

A meta-analysis of observational studies concluded that adherence to the MedDiet in women is not significantly associated with a reduced risk of metabolic syndrome. However, the subgroup analysis of women was based only on two of the 14 included studies, and the finding for combined sexes showed a substantial reduction of 19% (RR: 0.81 [95% CI: 0.71-0.92]) [65]. Other meta-analyses, which included both epidemiological and intervention studies, came to a similar result for combined sexes, but did not explore the effect in women alone [66,67].

Meta-analyses of the effect of the MedDiet on metabolic syndrome found that fasting glucose levels were slightly reduced, by about 0.1-0.3 mmol/L (2-6 mg/dL) [66,67]. In a sample of postmenopausal women, it was reduced by 0.4 mmol/L (7 mg/dL) [68].

A meta-analysis of prospective studies of dietary patterns and type 2 diabetes found that adherence to the MedDiet (RR comparing extreme quintiles: 0.87 [95% CI: 0.82-0.93]), as well as to the experimental interventions in the Dietary Approaches to Stop Hypertension (DASH) (RR: 0.81 [95% CI: 0.72-0.92]) and the Alternative Healthy Eating Index (AHEI) studies (RR: 0.79 [95% CI: 0.69-0.90]), were associated with significant risk reductions in the incidence of type 2 diabetes. [70].

The US Atherosclerosis Risk in Communities study prospective cohort without diabetes, CVD, or cancer at baseline (n = 11,991, mean age 54 years at study entry, 56% female, 75% white) with a median follow-up of 22 years also found lower diabetes risk with the MedDiet. [71]. Furthermore, associations were stronger for black versus white participants and weaker for obese versus those with normal body mass index (BMI), but there was no difference in the effect according to sex.

A systematic review of all meta-analyses and RCTs with electronic searches up to January 2015 concluded that the MedDiet was associated with better glycemic control and cardiovascular risk factors than control diets, including lower-fat diets, suggesting that it is suitable for the overall management of type 2 diabetes in both sexes [72]. A subsequent network meta-analysis of randomized trials found that the MedDiet produced beneficial improvements in glycemic control, weight loss, and cardiovascular risk factors in people with type 2 diabetes [73].

An RCT which included women (mean age 50 years) newly diagnosed with type 2 diabetes compared the MedDiet with a low-fat diet. Reductions in weight, glycated hemoglobin (HbA1c) and systolic blood pressure were significantly greater in the MedDiet group than in the low-fat group [74].

In summary, adherence to the MedDiet reduces the risk of developing type 2 diabetes and improves its course, both in peri- or postmenopausal women and men. Although the effects are small, the MedDiet may be preferable to restrictive diets such as a low-fat diet. Further observational studies and RCTs in peri- and postmenopausal women are required to improve the quality of the evidence.

6. The Mediterranean diet and osteoporosis

As the burden of osteoporotic fracture in terms of both mortality and disability is increasing, not surprisingly the effect of nutrition on bone health has attracted considerable attention [75]. Adequate intakes of calcium and vitamin D are recommended in most osteoporosis guidelines [76] and there is growing interest on the role of protein intake in bone accrual during childhood and adolescence and skeletal preservation in the post-reproductive years [77,78].

A post-hoc analysis of the Women’s Health Initiative observational study published in 2016 found that women scoring in the highest quintile of the MedDiet had a 20% lower risk of hip, but not total, fracture [79]. A meta-analysis published in 2017 of three prospective cohort studies, including the Women’s Health Initiative observational study [79], concluded that only observational evidence on the effect of the MedDiet on bone health was available and that there was lack of agreement in the findings for hip fracture [80].

Subsequently, a one-year randomized trial undertaken across five European centers with 1294 participants (mean ± 5 SD: 70.9 ± 4.0 years; 46% women) of a Mediterranean-like dietary pattern and a vitamin D3 supplement (400 IU /d) found no effect on bone mineral density (BMD) (site-specific or whole-body) [81]. Osteoporotic fracture was not evaluated. Subgroup analysis of individuals with osteoporosis
at baseline (site-specific BMD T-score ≤ −2.5 SDs) showed that the MedDiet attenuated the expected decline in femoral neck bone mineral density (n = 24 and 30 in the MedDiet and control groups, respectively; P = 0.04) but had no effect on lumbar spine or whole-body parameters. The authors concluded that the intervention had no effect on BMD in the normal age-related range, but significantly reduced the rate of loss of bone at the femoral neck in individuals with osteoporosis. Thus, further research is needed regarding the MedDiet and skeletal health and osteoporotic fracture; however, the MedDiet may be considered an appropriate diet for women with osteoporosis but should not be used as the primary treatment strategy.

7. The Mediterranean diet and cognitive and mental health

In 2017 it was estimated that 792 million people lived with a mental health disorder. This is slightly more than one in 10 people globally (10.7 % overall, 9.3 % of men and 11.9 % of women) [82]. Research on the effects of the MedDiet on cognition and mood disorders is summarized below.

7.1. Cognition

Dementia has become a public health priority: in 2016, the global number of individuals living with dementia was 43.8 million, having increased from 20.2 million in 1990. More women than men had dementia in 2016 (27.0 million vs 16.8 million), and dementia was the fifth leading cause of death globally, accounting for 2.4 million deaths [83]. The World Health Organization has recognized diet as an important factor in reducing the risk of cognitive decline and dementia [84]. Several cohort studies have been undertaken. A 2014 meta-analysis with five eligible studies found that in cognitively normal individuals, higher adherence to the MedDiet was associated with a reduced risk of mild cognitive impairment (HR: 0.73 [95 %CI: 0.56–0.96]; P = 0.02) and Alzheimer’s disease (HR: 0.64 [95 %CI: 0.46–0.89]; P = 0.007) [85]. In a 2017 systematic review and meta-analysis of nine cohort studies with a total of 34,168 participants, the pooled analysis showed that the highest MedDiet category score, compared with the lowest category, was inversely associated with the development of cognitive disorders, and the pooled RR was 0.79 (95 %CI: 0.70–0.90) [86]. Protective effects have been reported in subsequent cohort studies undertaken in Europe, the USA and China [87–89]. Furthermore, higher self-reported MedDiet adherence is associated with beneficial effects on cognitive and neuroimaging phenotypes associated with Alzheimer’s disease [90].

A prospective cohort study of 16,058 postmenopausal women found that long-term adherence to a MedDiet pattern was linearly associated with improved cognitive scores in adjusted models [91]. However, in a study of 2,504 peri- and postmenopausal women with CVD, which per se increases the risk of cognitive decline, greater short-term adherence to the MedDiet had no effect on cognition [92]. This aligns with other findings regarding diet and cognition. For instance, long-term adherence to a diet that includes frequent consumption of fish, such as the traditional MedDiet, is associated with improved cognition, but short-term interventions, whether dietary or supplemental, have no effect [93].

7.2. Mood and depression

The important effect of diet on mood is such that lifestyle and dietary changes are incorporated in psychiatric clinical practice guidelines [see for example [94]]. Systematic reviews and meta-analyses have found that adherence to the MedDiet reduces the risk of depression [see for example [95–100]]. However, the Whitehall II Study could not detect an effect of the MedDiet on the recurrence of depressive symptoms [101]. Nevertheless, the SUN study, which followed individuals free of depression at baseline, found that adherence to the MedDiet (comparison of the highest vs the lowest quartile) was associated with a 25 % mean reduction in depression diagnoses at two-year follow-up [102]. Furthermore, the Women’s Health Initiative Observational Study found that a diet with a high glycemic index was a risk factor for depression [103].

A well-controlled RCT which recruited participants with major depressive disorder, mostly women in the early peri-menopause, found that adherence to the MedDiet for 3 months significantly improved depressive symptoms as well as depression remission, with a number needed to treat of 4.1 (95 %CI: 2.3–27.8) [104].

8. The Mediterranean diet and breast cancer

Reports on a possible association between the MedDiet and the risk of breast cancer have been contradictory [105]. The EPIC cohort study, drawing on populations across Europe, found an inverse association with the risk of breast cancer in postmenopausal women (HR: 0.93 [95 %CI: 0.88–1.00]) [106]. The Swedish Women’s Lifestyle and Health cohort reported no association [107]. Whilst a Western-style dietary pattern was found to increase the risk of breast cancer, a case-control study found that high adherence to the MedDiet decreased the risk (OR: 0.56 [95 %CI: 0.40–0.79]) [108]. The PREDIMED randomized trial reported that after 4.8 years, the MedDiet supplemented with olive oil significantly decreased the risk of breast cancer by 69 % (HR: 0.31 [95 %CI: 0.23–0.77]), but no statistically significant effect was found for the MedDiet supplemented with nuts [109]. Furthermore, the Women’s Health Initiative Dietary Modification Randomized Trial found that adoption of a low-fat diet with increased vegetable, fruit, and grain intake may reduce the risk of death as a result of breast cancer in postmenopausal women [110]. Inverse associations have been reported between the MedDiet and breast cancer subtypes, including ER-/PR-tumors (HR: 0.80 [95 %CI: 0.65–0.99]) and triple-negative tumors (OR: 0.32 [95 %CI: 0.15–0.66]) [106,108].

9. The Mediterranean diet and all-cause mortality

As shown in Table 1, the MedDiet has been found to be inversely associated with both CVD-related and all-cause mortality in both Mediterranean and non-Mediterranean populations [12,111]. Furthermore, a systematic review and meta-analysis in 2019 involving 29 prospective studies with 1,676,901 participants, 221,603 of whom died in the study period, found that the risk of all-cause mortality linearly decreased with increase in adherence to a MedDiet [10].

10. Summary

The MedDiet is a non-restrictive dietary pattern which has proved broadly acceptable to non-Mediterranean as well as Mediterranean populations. While there is not one exact MedDiet, the defining characteristics include: high intake of olive oil, nuts, vegetables, fruits, and cereals; moderate intake of fish and poultry; low intake of dairy products, red meat, processed meats, and sweets; and wine in moderation, consumed with meals.

In peri- and post-menopausal women, long-term high adherence may:

- reduce cardiovascular risk, and the incidence of cardiovascular events and death
- maintain bone mineral density whilst leading to more favorable body composition
- improve bone mineral density in women with osteoporosis
- help to prevent cognitive decline
- reduce the risk of breast cancer
- reduce the risk of all-cause mortality.

In peri- and post-menopausal women, short-term high adherence
may:

- improve vasomotor symptoms
- improve cardiovascular risk factors such as blood pressure, cholesterol, and blood glucose levels
- improve mood and symptoms of depression.

Contributors

Antonio Cano, Skye Marshall, Irene Zolfaroli, and Margaret Rees prepared the initial draft, which was circulated to all other named authors (EMAS board members) for comments and approval; production was coordinated by Irene Lambrinoudaki and Margaret Rees.

Conflict of interest

Antonio Cano: In the past three years, Dr Antonio Cano has received speakers’ honoraria from Shionogi and consulting fees from Pierre-Fabre Iberica and Mitsubishi Tanabe Pharma.

Skye Marshall: In the past three years, Dr Skye Marshall has been partially supported by an Innovation Connections grant (Commonwealth of Australia) and has worked on research projects funded by industry. Dr Marshall declares no conflicts of interest.

Irene Zolfaroli: None declared.

Johannes Bitzer: In the past three years Prof. Bitzer has served on advisory boards of Bayer AG, Merck, MSD, Teva, Theramex, Mithra, Actavis, Ava, Natural cycles, Böhringer Ingelheim, Effik, Lilly, Exelitis, Vifor, Libbs, Gedeon Richter, HRA and has given invited lectures and received honoraria by Bayer Pharma AG, Merck, Johnson and Johnson, Teva, Mylan, Allergan, Abbott, Lilly, Pfizer, Exelitis, Libbs, HRA, Pierre Fabre.

Iuliana Ceausu: None declared.

Peter Chedraui: None declared.

Patrice Lopes: None declared.

References


Funding

No funding was sought or secured for the preparation of this position statement.

Provenance and peer review

This article is an EMAS position statement and was not externally peer reviewed.

Acknowledgements

Peter Chedraui is supported by the Sistema de Investigación y Desarrollo (SINDE) and the Vice-Rectorado de Investigación & Postgrado (VRIP) of the Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, through grant No. SIU-318-853-2014 (The Omega II, Women’s Health Project). Neither SINDE nor VRIP have had involvement in the writing of this position statement.